To hear about similar clinical trials, please enter your email below
Trial Title:
Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT ID:
NCT00254319
Condition:
Untreated Advanced Non-Small Cell Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Bevacizumab
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Unknown status
Study design:
Allocation:
Non-Randomized
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Avastin, Alimta
Summary:
Avastin is a novel antiangiogenic agent that has recently been shown to improve response
rates and survival of patients with advanced nonsquamous non-small cell lung cancer when
added to front-line carboplatin/paclitaxel chemotherapy, and is now being routinely
incorporated into the treatment of these patients. Alimta is a recently approved
chemotherapeutic that has shown activity against non-small cell lung cancer when given
alone and in combination with carboplatin, has a favorable toxicity profile andrequires
only a brief (10 minute) infusion time. Therefore we propose to study the combination of
Avasin, Alimta, and Carboplatin administered as front-line therapy to patients with
advanced nonsquamous non-small cell lung cancer.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
I am 18 years of age or older. I have advanced non-small lung cancer. I have not had any
major surgical procedures within 28 days prior to my starting treatment.
I have high blood pressure that is controlled. I am not on heparin, coumadin or lovonox
for treatment of medical conditions. I do not have serious wound healing problems. I have
not received any previous treatment, except radiation therapy for my disease.
Exclusion Criteria:
-
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
The CINJ at Cooper University Hospital
Address:
City:
Voorhees
Zip:
08043
Country:
United States
Status:
Recruiting
Investigator:
Last name:
James Stevenson, MD
Email:
Principal Investigator
Investigator:
Last name:
Generosa Grana, MD
Email:
Sub-Investigator
Lead sponsor:
Agency:
The Cooper Health System
Agency class:
Other
Source:
The Cooper Health System
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT00254319
